Literature DB >> 11441209

Neuroprotective effect of sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) is linked to reduced neuronal nitric oxide production.

T Goyagi1, S Goto, A Bhardwaj, V L Dawson, P D Hurn, J R Kirsch.   

Abstract

BACKGROUND AND
PURPOSE: The potent final sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl) piperidine (PPBP) provides neuroprotection in experimental stroke. We tested the hypothesis that PPBP attenuates striatal tissue damage after middle cerebral artery occlusion (MCAO) by a mechanism involving reduction of ischemia-evoked nitric oxide (NO) production. Furthermore, we determined whether the agent fails to protect ischemic brain when neuronal nitric oxide synthase (nNOS) is genetically deleted or pharmacologically inhibited (selective nNOS inhibitor, 7-nitroindazole [7-NI]).
METHODS: Halothane-anesthetized adult male Wistar rats were subjected to 2 hours of MCAO by the intraluminal filament occlusion technique. All physiological variables were controlled during the ischemic insult. In vivo striatal NO production was estimated via microdialysis by quantification of local, labeled citrulline recovery after labeled arginine infusion. In a second series of experiments, nNOS null mutants (nNOSKOs) and the genetically matched wild-type (WT) strain were treated with 90 minutes of MCAO. Brains were harvested at 22 hours of reperfusion for measurement of infarction volume by triphenyltetrazolium chloride histology.
RESULTS: PPBP attenuated infarction volume at 22 hours of reperfusion in cerebral cortex and striatum and markedly attenuated NO production in ischemic and nonischemic striatum during occlusion and early reperfusion. Treatment with 7-NI mimicked the effects of PPBP. In WT mice, infarction volume was robustly decreased by both PPBP and 7-NI, but the efficacy of PPBP was not altered by pharmacological nNOS inhibition in combined therapy. In contrast, PPBP did not decrease infarction volume in nNOSKO mice.
CONCLUSIONS: These data suggest that the mechanism of neuroprotection of PPBP in vivo is through attenuation of nNOS activity and ischemia-evoked NO production. Neuroprotective effects of PPBP are lost when nNOS is not present or is inhibited; therefore, PPBP likely acts upstream from NO generation and its subsequent neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11441209     DOI: 10.1161/01.str.32.7.1613

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  27 in total

1.  The sigma-1 receptor chaperone as an inter-organelle signaling modulator.

Authors:  Tsung-Ping Su; Teruo Hayashi; Tangui Maurice; Shilpa Buch; Arnold E Ruoho
Journal:  Trends Pharmacol Sci       Date:  2010-10-01       Impact factor: 14.819

Review 2.  Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders.

Authors:  Teruo Hayashi; Shang-Yi Tsai; Tomohisa Mori; Michiko Fujimoto; Tsung-Ping Su
Journal:  Expert Opin Ther Targets       Date:  2011-03-05       Impact factor: 6.902

3.  Activation of the sigma-1 receptor by haloperidol metabolites facilitates brain-derived neurotrophic factor secretion from human astroglia.

Authors:  Dhwanil A Dalwadi; Seongcheol Kim; John A Schetz
Journal:  Neurochem Int       Date:  2017-02-08       Impact factor: 3.921

4.  Sigma receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine modulates neuronal nitric oxide synthase/postsynaptic density-95 coupling mechanisms and protects against neonatal ischemic degeneration of striatal neurons.

Authors:  Zeng-Jin Yang; Erin L Carter; Michel T Torbey; Lee J Martin; Raymond C Koehler
Journal:  Exp Neurol       Date:  2009-10-31       Impact factor: 5.330

5.  Activation of Sigma-1 Receptor Enhanced Pericyte Survival via the Interplay Between Apoptosis and Autophagy: Implications for Blood-Brain Barrier Integrity in Stroke.

Authors:  Yuan Zhang; Xiaotian Zhang; Qiangqiang Wei; Shuo Leng; Cai Li; Bing Han; Ying Bai; Huibin Zhang; Honghong Yao
Journal:  Transl Stroke Res       Date:  2019-07-09       Impact factor: 6.829

6.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

Review 7.  Perinatal hypoxic-ischemic brain injury in large animal models: Relevance to human neonatal encephalopathy.

Authors:  Raymond C Koehler; Zeng-Jin Yang; Jennifer K Lee; Lee J Martin
Journal:  J Cereb Blood Flow Metab       Date:  2018-08-28       Impact factor: 6.200

Review 8.  Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria.

Authors:  Guy C Brown; Anna Bal-Price
Journal:  Mol Neurobiol       Date:  2003-06       Impact factor: 5.590

9.  An alpha-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain.

Authors:  Mahmood Amiry-Moghaddam; Takashi Otsuka; Patricia D Hurn; Richard J Traystman; Finn-Mogens Haug; Stanley C Froehner; Marvin E Adams; John D Neely; Peter Agre; Ole Petter Ottersen; Anish Bhardwaj
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-10       Impact factor: 11.205

10.  Sigma receptor agonists provide neuroprotection in vitro by preserving bcl-2.

Authors:  Sufang Yang; Anish Bhardwaj; Jian Cheng; Nabil J Alkayed; Patricia D Hurn; Jeffrey R Kirsch
Journal:  Anesth Analg       Date:  2007-05       Impact factor: 5.108

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.